Patents Issued in January 18, 2024
  • Publication number: 20240018123
    Abstract: The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 18, 2024
    Inventors: Jong Yeon HWANG, Jae Du HA, Hyun Jin KIM, Sung Yun CHO, Pilho KIM, Chong Ock LEE, Jeong Hoon KIM, Byoung Chul PARK, Sung Goo PARK, Sunhong KIM, Yuri CHOI, Yaejin WOO, Song Hee LEE, Je Ho RYU, Jungmin AHN, Ji Youn PARK, Onnuri BAE, Hanwool KIM
  • Publication number: 20240018124
    Abstract: Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
    Type: Application
    Filed: March 17, 2022
    Publication date: January 18, 2024
    Inventors: Tianwei MA, Feng SHI, Lichao FANG, Zheng HUANG, Hua Viola LIN, Yue XIAO
  • Publication number: 20240018125
    Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 18, 2024
    Inventors: Jean-Philippe HERBEUVAL, Anaïs BARRÉ, Julie CASSOU, Stanislas MAYER, Patrick BAZZINI
  • Publication number: 20240018126
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Inventors: Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
  • Publication number: 20240018127
    Abstract: The invention relates to a light emitting organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule consists of a first chemical moiety with a structure of Formula I.
    Type: Application
    Filed: July 22, 2021
    Publication date: January 18, 2024
    Inventors: Damien THIRION, Damien JOLY, Michael DANZ
  • Publication number: 20240018128
    Abstract: Compounds of the formula (I) wherein G1, G2, X, R1, R2 R3, and R4 are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling animal pests, including arthropods and in particular insects, molluscs, nematodes or representatives of the order Acarina.
    Type: Application
    Filed: August 31, 2021
    Publication date: January 18, 2024
    Applicant: SYNGENTA CROP PROTECTION AG
    Inventors: Vikas SIKERVAR, Swarnendu SASMAL, Michel MUEHLEBACH, André STOLLER, Daniel EMERY, André JEANGUENAT, Anke BUCHHOLZ, Benedikt KURTZ
  • Publication number: 20240018129
    Abstract: Disclosed herein are compounds of formula (I) that are PU.1 inhibitors. Also provided herein are methods or preparing these compounds.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 18, 2024
    Applicant: S-Infinity Pharmaceuticals
    Inventors: Xiaoguang LEI, Hong WU, Xin WANG, Ningning YAO, Fusheng GUO
  • Publication number: 20240018130
    Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.
    Type: Application
    Filed: September 14, 2023
    Publication date: January 18, 2024
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
  • Publication number: 20240018131
    Abstract: Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
    Type: Application
    Filed: July 6, 2023
    Publication date: January 18, 2024
    Inventors: Wenjin Yang, Kai-Wei Chang, Suying Liu, Cheng-Han Tsai
  • Publication number: 20240018132
    Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula (I) to (IV) for the treatment of cancer.
    Type: Application
    Filed: October 26, 2021
    Publication date: January 18, 2024
    Inventors: Sandip GAVADE, Sangeeta SRIVASTAVA, Prashant KHARKAR, Maithili ATHAVALE
  • Publication number: 20240018133
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: September 7, 2023
    Publication date: January 18, 2024
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, SeungWon Chung, Qingwei Zhang, Lei Shi, Kathleen J. Murauski, Michael J. Dart, John T. Randolph, Hanae Benelkebir
  • Publication number: 20240018134
    Abstract: The present invention provides 6-substituted pyridazine compounds of formula (I) which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or delaying progression of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer or a prodrug thereof.
    Type: Application
    Filed: August 3, 2021
    Publication date: January 18, 2024
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Chandrasekhar Abbineni, Susanta Samajdar, Bilash Kuila, Subhendu Mukherjee, Suraj Tatyasaheb Gore
  • Publication number: 20240018135
    Abstract: The present invention relates to a novel compound having inhibitory activity against O-GlcNAcase and a use thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 18, 2024
    Applicant: MEDIFRON DBT INC.
    Inventors: Hee KIM, Hee Jin HA, Hye Min JU, Ki Sun ROH, Jae Hong IM, Jin Mi KANG, Minyoung Lee
  • Publication number: 20240018136
    Abstract: The disclosure is directed to compounds of Formula I pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: March 8, 2023
    Publication date: January 18, 2024
    Inventors: Jincong Zhuo, Andrew Combs
  • Publication number: 20240018137
    Abstract: Provided is a compound represented by formula (1): In the formula, A represents a polymerizable group; L represents an optionally branched (n+1)-valent linking group; R1 represents an aromatic ring group optionally having a substituent; R2 represents a monovalent organic group optionally having a substituent; X1 and X2 each independently represent an oxygen atom, a sulfur atom, or a nitrogen atom optionally having a substituent; m represents an integer of 0 or 1; n represents an integer of 1 to 3; and p represents an integer of 0 or 1. The two R1s may be bonded together at any position to form a ring structure and R1=R2, X1=X2, and p=1 do not hold simultaneously. The compound simultaneously has a high refractive index and high transparency.
    Type: Application
    Filed: September 21, 2023
    Publication date: January 18, 2024
    Applicant: MITSUBISHI CHEMICAL CORPORATION
    Inventors: Shuji YAMASHITA, Akiko Yabe, Tatsuya Ishikawa, Ken Sato, Asato Tanaka
  • Publication number: 20240018138
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof. The compound of formula (I) can be useful for the treatment of a disease or condition for which a cGAS inhibitor is indicated. In some embodiments, the compound or its pharmaceutically acceptable salt, solvate, ester or prodrug thereof can be used for the treatment of an autoinflammation or an autoimmune disease such as systemic lupus erythematosus (SLE), Aicardi-Goutieres syndrome (AGS), nonalcoholic steatohepatitis (NASH), Age-dependent macular degeneration, Myocardial infarction, Acute pancreatitis, Ischemic stroke, Sporadic aortic aneurysm and dissection, Chronic lung disease, Inflammatory bowel disease, Parkinson's disease, Traumatic brain injury or Amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: September 23, 2021
    Publication date: January 18, 2024
    Inventors: Lee Fader, Jason Burch, Miguel St-Onge, Stéphane Dorich
  • Publication number: 20240018139
    Abstract: Antagonistic small-molecule compounds having a function of inhibiting endosomal Toll-like receptors (TLRs), more specifically, a small-molecule compound for inhibiting TLR3/7/8/9 signaling pathways, a composition for inhibiting Toll-like receptors, containing the compound; and a composition for preventing or treating autoimmune diseases, inflammatory diseases, or viral diseases are disclosed. The novel compound shows very significant results in a systemic lupus erythematosus animal model by not only preventing TNF-? secretion induced by poly I:C (TLR3 agonist), imiquimod (TLR7 agonist), TL8-506 (TLR8 agonist), or ODN2395 (TLR9 agonist), but also inhibiting the production of inflammatory cytokines. This suggests that the compound is also useful for the prevention or treatment of TLR3, TLR7, TLR8 or TLR9-associated autoimmune diseases, inflammatory diseases and viral diseases.
    Type: Application
    Filed: November 25, 2021
    Publication date: January 18, 2024
    Applicant: S&K THERAPEUTICS
    Inventors: Sangdun CHOI, Chang Hee SUH, Uisuk JEONG, Yangseon CHOI, Wook-Young BAEK, Kevin Jaesuk CHOI, Chun Yong IM, Doohyun LEE, Nam Hui KIM, Seungyeon LEE, Hyo-Ji KIM, Sang Kyoon KIM, Yoojin OH, So Young KIM, Ye Ri HAN
  • Publication number: 20240018140
    Abstract: The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).
    Type: Application
    Filed: September 15, 2021
    Publication date: January 18, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Melissa C. Ford, Mark E. Fraley, Kristen L.G. Jones, H. Marie Loughran, James J. Mulhearn, Anthony J. Roecker, Kathy M. Schirripa, Ling Tong
  • Publication number: 20240018141
    Abstract: The present disclosure provides compounds of Formula I: (I), pharmaceutically acceptable salts thereof, conjugates thereof, as well as methods of synthesizing and using such compounds, e.g., in a method of treating a pathological condition in a subject. The compounds described herein can have immunomodulatory properties and can interact with a Toll-like receptor as described herein.
    Type: Application
    Filed: August 21, 2023
    Publication date: January 18, 2024
    Inventors: David M. FERGUSON, Peter Gustav LARSON
  • Publication number: 20240018142
    Abstract: The present application provides a crystalline form of tolebrutinib, an amorphous form, and a method of preparation thereof and a use thereof, and the crystalline form of tolebrutinib provided in the present application has at least one of the following advantages: good stability, low moisture attraction, uniform particle size distribution, solubility meeting the requirements for medicinal use, stable storage, avoiding phase transformation of the drug in the process of development and in storage, and a reliable method for the preparation thereof, which has a great development value. The amorphous form of tolebrutinib provided in this application, while possessing better solubility than that of tolebrutinib in the crystalline state, still possesses good stability of placement and acceptable hygroscopicity, and has high medicinal value.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 18, 2024
    Applicant: HANGZHOU SOLIPHARMA CO., LTD.
    Inventors: Xiaohong SHENG, Xiaoxia SHENG, Yu DAI
  • Publication number: 20240018143
    Abstract: The present invention relates to a process for the preparation of a compound (I), and its solid form, which is a modulator of ?-secretase and may be useful for prophylaxis and treatment of a disease associated with the deposition of ?-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
    Type: Application
    Filed: June 8, 2023
    Publication date: January 18, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Weichun Chen, Guocai Zhang
  • Publication number: 20240018144
    Abstract: Provided herein are processes for synthesizing compounds useful as EGFR modulators.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 18, 2024
    Inventors: Jason Christopher Rech, Mukesh K. Nyati, Fan Fang, Lei Zhang, Julian Paul Henschke
  • Publication number: 20240018145
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing influenza. The compounds are cap-dependent endonuclease inhibitors.
    Type: Application
    Filed: July 22, 2021
    Publication date: January 18, 2024
    Applicants: Merck Sharp & Dohme LLC, COCRYSTAL PHARMA, INC.
    Inventors: Yonglian Zhang, John A. McCauley, Michael Man-Chu Lo, Liangqin Guo, Kake Zhao, Frank Bennett, Ronald M. Kim, Reynalda Keh DeJesus, Valerie W. Shurtleff, Manuel de Lera Ruiz, Michael Plotkin, Hua Su, James Fells, Brendan M. Crowley, Harry R. Chobanian, Mark W. Embrey, Gregori J. Morriello
  • Publication number: 20240018146
    Abstract: The present disclosure is directed to adenine analogs, methods of making adenine analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: February 22, 2021
    Publication date: January 18, 2024
    Applicant: MITOKININ, INC.
    Inventors: Nicholas Thomas HERTZ, Dara DITSWORTH, Johan BARTHOLOMEUS, Shawn JOHNSTONE, Randall Marcelo CHIN, Robert DEVITA, Philippe MCGEE, Julien DANSEREAU, Rishi RAKHIT
  • Publication number: 20240018147
    Abstract: Provided are a salt of a compound for degrading BTK, and/or a crystal form, preparation therefor, and an application thereof.
    Type: Application
    Filed: September 8, 2021
    Publication date: January 18, 2024
    Applicant: HAISCO PHARMACEUTICALS PTE. LTD.
    Inventors: Chen Zhang, Yuting Liao, Jianmin Wang, Longbin Huang, Guozhi Zhu, Yao Li, Pangke Yan
  • Publication number: 20240018148
    Abstract: The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: February 2, 2023
    Publication date: January 18, 2024
    Inventors: Bart VANDERHOYDONCK, Arnaud MARCHAND, Wim SMETS, Aurélie CANDI, Matthias VERSELE
  • Publication number: 20240018149
    Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the degrading target proteins associated with a disease or condition.
    Type: Application
    Filed: June 29, 2023
    Publication date: January 18, 2024
    Inventors: Chu-Chiang LIN, Hung-Chuan CHEN, Pei-Chin Xizhou, Chih-Chang CHOU
  • Publication number: 20240018150
    Abstract: The present invention provides a new compound having a structure of Formula I, or an enol compound, a pharmaceutically acceptable salt, a deuterated derivative, a hydrate or solvate, an active metabolite, a polymorph, an ester, an optical isomer or a prodrug thereof, a pharmaceutical composition comprising the compound having a structure of Formula I, and use thereof in the preparation of a drug that is a Bruton's tyrosine kinase (BTK) inhibitor or has selectivity for a BTK mutant (C481S) to prevent or treat immune-related diseases, autoimmune diseases or cancers.
    Type: Application
    Filed: August 23, 2023
    Publication date: January 18, 2024
    Inventors: Lingzhi XIE, Dandan QIAO, Das DEBASIS, Jian HONG
  • Publication number: 20240018151
    Abstract: The invention relates to novel inhibitors of the PIKFYVE, a phosphoinositide kinase, useful for the treatment of diseases or disorders characterized by dysregulation of phosphoinositide mediated signal transduction pathways, including hyperproliferative diseases, autoimmune diseases, Crohn's disease, psoriasis, neurological diseases, diabetes, corneal fleck dystrophy, and viral infection (including HIV, Ebola, and coronavirus infections). The invention further relates to pharmaceutical compositions comprising PIKFYVE inhibitors and methods of treatment of such diseases and disorders.
    Type: Application
    Filed: October 19, 2021
    Publication date: January 18, 2024
    Inventor: Vinod F. PATEL
  • Publication number: 20240018152
    Abstract: The present invention relates to a novel process for the preparation of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4, 5, 6, 7-tetrahydropyrazolo[1,5-a] pyrimidine-3-carboxamide of formula-1 or its salts. The present invention also relates to novel process for the preparation of intermediate compound of Formula-7 and recovery of the intermediate compound of Formula-12, which is used in the preparation of compound of Formula-7. The compounds of formula-1 & formula-7 are represented by following structural formulae.
    Type: Application
    Filed: November 15, 2022
    Publication date: January 18, 2024
    Applicant: MSN LABORATORIES PRIVATE LIMITED, R&D CENTER
    Inventors: Thirumalai Rajan SRINIVASAN, Eswaraiah SAJJA, Satyanarayana REVU, Srinivas Reddy GADE, Malla Reddy ADLA, Naveen RAGAM
  • Publication number: 20240018153
    Abstract: Provided herein are benzenesulfonamide compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 18, 2024
    Inventors: Patrick T. GUNNING, Jeff OMEARA, Siawash AHMAR, Graham L. SIMPSON, Peter HUNT, David Alexander ROSA, Ji Sung PARK
  • Publication number: 20240018154
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R4 and A are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 18, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Christa Ulrike OBST-SANDER, Antonio RICCI
  • Publication number: 20240018155
    Abstract: The present disclosure relates to novel crystalline form of a tosylate salt of diazadicyclic compound and preparation method thereof. Form A of formula (I) tosylate of the present disclosure have advantages in at least one aspect of solubility, melting point, stability, dissolution, hygroscopicity, adhesion, flowability, bioavailability, processability, purification ability, formulation production, and safety, etc., which provides a new and better choice for the preparation of drugs containing formula (I) tosylate, and is of great significance for the drug development.
    Type: Application
    Filed: June 8, 2021
    Publication date: January 18, 2024
    Applicant: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Xia LU, Xiaoyu ZHANG
  • Publication number: 20240018156
    Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: March 6, 2023
    Publication date: January 18, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
  • Publication number: 20240018157
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.
    Type: Application
    Filed: December 24, 2020
    Publication date: January 18, 2024
    Inventors: Shulu Feng, Morgan Lawrenz, Goran Krilov, Andrew Placzek, Zhe Nie, Lynnie Trzoss, Michael Trzoss, Haifeng Tang, H. Rachel Lagiakos
  • Publication number: 20240018158
    Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
    Type: Application
    Filed: May 15, 2023
    Publication date: January 18, 2024
    Inventors: Hong Lin, Philip Pitis, Liang Lu, Andrew Paul Combs
  • Publication number: 20240018159
    Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
    Type: Application
    Filed: August 22, 2023
    Publication date: January 18, 2024
    Inventors: Gang QIN, Tony Yantao ZHANG, Guangming CHEN, Paul H. SONG, Boyu ZHONG, Mingyu HU
  • Publication number: 20240018160
    Abstract: Disclosed herein is a method of making and/or isolating isoidide, a composition including a mixture including non-esterified isoidide and one or both compounds selected from the group consisting of esterified isosorbide and esterified isomannide and a method of using of such composition for making and/or isolating isoidide. Further disclosed herein is a method including a step of selective esterification of a mixture of dianhydrohexitol isomers including isoidide for separating isoidide from said mixture of dianhydrohexitol isomers. Moreover, a method of making a polymer including isoidide monomers or modified isoidide monomers is disclosed.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 18, 2024
    Inventors: Mark MASCAL, Jan SASKA, Alois KINDLER, Stephan ZUEND, Saikat DUTTA
  • Publication number: 20240018161
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 18, 2024
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Andrew DINH, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Mark Thomas MILLER, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Lino VALDEZ, Jinglan ZHOU
  • Publication number: 20240018162
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
    Type: Application
    Filed: November 9, 2022
    Publication date: January 18, 2024
    Inventors: John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
  • Publication number: 20240018163
    Abstract: The invention relates to a compound of formula (I) wherein R1—R4 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 15, 2023
    Publication date: January 18, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Virginie BROM, Cosimo DOLENTE, Delphine GAUFRETEAU, Nadine GRETHER, Fionn Susannah O'HARA, Matilde PIRAS, Hasane RATNI, Michael REUTLINGER, Walter VIFIAN, Claudio ZAMBALDO
  • Publication number: 20240018164
    Abstract: The present invention relates to a polycyclic aromatic derivative compound and a high efficiency and long lifetime organoelectroluminescent device which has significantly improved luminous efficiency by using same. The present invention can implement an organoelectroluminescent device with high efficiency and long lifetime, and thus can be effectively used for industrial applications including flat display devices, flexible display devices, monochromatic or white flat lighting devices, and monochromatic or white flexible lighting devices.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 18, 2024
    Inventors: Bong-ki SHIN, Sung-hoon JOO, Byung-sun YANG, Ji-hwan KIM, Hyeon-jun JO, Sung-eun CHOI
  • Publication number: 20240018165
    Abstract: The invention pertains to an organic molecule for use in optoelectronic devices.
    Type: Application
    Filed: October 11, 2021
    Publication date: January 18, 2024
    Inventors: Stefan SEIFERMANN, Daniel ZINK, Damien THIRION
  • Publication number: 20240018166
    Abstract: Disclosed herein are NLRP3 inflammasome inhibitors and compositions thereof. Also disclosed herein are methods including administering a therapeutically effective amount of a composition comprising at least one NLRP3 inflammasome inhibitor to a subject in need thereof.
    Type: Application
    Filed: November 23, 2021
    Publication date: January 18, 2024
    Inventors: Bin LIU, Jiangchao YAO, Thomas HAIMOWITZ, Christopher BENETATOS, Stephen M. CONDON, Steven A. BOYD
  • Publication number: 20240018167
    Abstract: The described process synthesizes a halide-free single-site borane compound product tris(ortho-carboranyl)borane, or BoCb3. BoCb3 has Lewis superacid properties. The compounds, BoCb3, are thermally stable, and not reactive towards oxygen, but are sensitive to water. The characteristic high fluoride ion affinity is further translated to the catalytic C—F bond activation reactions of the unactivated alkyl fluorides towards the reduction and C—C bond forming reactions with silanes, and Fridel-Crafts type reactions with arenes. The potential of the synthesized Lewis acid as a catalysis is anticipated.
    Type: Application
    Filed: July 14, 2023
    Publication date: January 18, 2024
    Applicant: BAYLOR UNIVERSITY
    Inventors: CALEB MARTIN, MANJUR OYASIM AKRAM
  • Publication number: 20240018168
    Abstract: The present invention discloses a compound with multiple resonance characteristics and an organic electroluminescent device containing the compound. In the present invention, by introducing a bridged cyclic alkyl group, the rigidity of the compound is increased, the thermal stability and glass transition temperature of a host material can be effectively improved while the dispersion of guest molecules in the material is maintained, and the lifetime of a blue-light device is significantly prolonged. The compound provided by the present invention is suitable for blue host/dopant systems and organic electroluminescent devices of blue-series AM-OLEDs, and organic electroluminescent devices containing the compound have a higher external quantum efficiency, a lower driving voltage, and a particularly excellent lifetime.
    Type: Application
    Filed: September 21, 2023
    Publication date: January 18, 2024
    Applicant: SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIAL CO., LTD.
    Inventors: Zaifeng XIE, Tianyu WEI, Yubin XING, Lingwei XU, Songyuan LIU
  • Publication number: 20240018169
    Abstract: The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.
    Type: Application
    Filed: August 28, 2023
    Publication date: January 18, 2024
    Inventors: Anna Marie Pyle, Olga Fedorova, Erik Jagdmann, Michael Van Zandt, Lin Yuan, Albert DeBerardinis
  • Publication number: 20240018170
    Abstract: A novel method of making trialkylaluminum compounds and trialkylaluminum obtained thereby via exposing a solution of aluminum to an alkylating agent.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 18, 2024
    Applicant: UMICORE AG & CO. KG
    Inventor: Albert Barry LEESE
  • Publication number: 20240018171
    Abstract: The present disclosure pertains to the technical field of a catalyst. The present disclosure relates to a complexing agent for preparing titanium complexes for alpha olefin polymerization. In particular, the present disclosure provides titanium complexes for alpha olefin polymerization and methods of preparation thereof.
    Type: Application
    Filed: July 14, 2023
    Publication date: January 18, 2024
    Applicant: Hindustan Petroleum Corporation Limited
    Inventors: Nilesh Rajesh Mote, Monikangkana Talukdar, Yogesh Popatrao Patil, Bennet Chelliahn, Ramachandrarao Bojja
  • Publication number: 20240018172
    Abstract: Provided herein, in certain embodiments, are compounds of Formula I: or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
    Type: Application
    Filed: August 9, 2023
    Publication date: January 18, 2024
    Inventors: Imran Alibhai, Sofia de Achaval, Jeffrey Larson, Brad Henke